Publicacions en què col·labora amb EMILIA CERCENADO MANSILLA (35)

2023

  1. Activity of imipenem/relebactam against Enterobacterales and Pseudomonas aeruginosa in Spain. SMART 2016-2020

    Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, Vol. 36, Núm. 3, pp. 302-309

  2. An increase in erythromycin resistance in methicillin-susceptible Staphylococcus aureus from blood correlates with the use of macrolide/lincosamide/streptogramin antibiotics. EARS-Net Spain (2004–2020)

    Frontiers in Microbiology, Vol. 14

  3. Automatic Discrimination of Species within the Enterobacter cloacae Complex Using Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry and Supervised Algorithms

    Journal of clinical microbiology, Vol. 61, Núm. 4, pp. e0104922

  4. Pseudomonas aeruginosa antibiotic susceptibility profiles, genomic epidemiology and resistance mechanisms: a nation-wide five-year time lapse analysis

    The Lancet Regional Health - Europe, Vol. 34

  5. Significant increase of CTX-M-15-ST131 and emergence of CTX-M-27-ST131 Escherichia coli high-risk clones causing healthcare-associated bacteraemia of urinary origin in Spain (ITUBRAS-2 project)

    The Journal of antimicrobial chemotherapy, Vol. 78, Núm. 9, pp. 2291-2296

  6. Spanish Antibiogram Committee (COESANT) recommendations for cumulative antibiogram reports

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 41, Núm. 7, pp. 430-435

  7. Ten Issues for Updating in Community-Acquired Pneumonia: An Expert Review

    Journal of Clinical Medicine, Vol. 12, Núm. 21

2022

  1. Imipenem-Relebactam Susceptibility in Enterobacterales Isolates Recovered from ICU Patients from Spain and Portugal (SUPERIOR and STEP Studies)

    Microbiology spectrum, Vol. 10, Núm. 5, pp. e0292722

  2. In vitro activity of imipenem/relebactam against Pseudomonas aeruginosa isolates recovered from ICU patients in Spain and Portugal (SUPERIOR and STEP studies)

    The Journal of antimicrobial chemotherapy, Vol. 77, Núm. 11, pp. 3163-3172

2021

  1. A Large Multicenter Prospective Study of Community-Onset Healthcare Associated Bacteremic Urinary Tract Infections in the Era of Multidrug Resistance: Even Worse than Hospital Acquired Infections?

    Infectious Diseases and Therapy, Vol. 10, Núm. 4, pp. 2677-2699

  2. Antimicrobial activity of ceftolozane-tazobactam against Enterobacterales and Pseudomonas aeruginosa recovered during the Study for Monitoring Antimicrobial Resistance Trends (SMART) program in Spain (2016-2018)

    Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, Vol. 34, Núm. 3, pp. 228-237

  3. Distinct epidemiology and resistance mechanisms affecting ceftolozane/tazobactam in Pseudomonas aeruginosa isolates recovered from ICU patients in Spain and Portugal depicted by WGS

    The Journal of antimicrobial chemotherapy, Vol. 76, Núm. 2, pp. 370-379

  4. Predicting Pseudomonas aeruginosa susceptibility phenotypes from whole genome sequence resistome analysis

    Clinical Microbiology and Infection, Vol. 27, Núm. 11, pp. 1631-1637

2020

  1. From CLSI to EUCAST, a necessary step in Spanish laboratories

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 38, Núm. 2, pp. 79-83

  2. Recommendations of the Spanish Antibiogram Committee (COESANT) for selecting antimicrobial agents and concentrations for in vitro susceptibility studies using automated systems

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 38, Núm. 4, pp. 182-187

  3. WGS characterization of MDR Enterobacterales with different ceftolozane/tazobactam susceptibility profiles during the SUPERIOR surveillance study in Spain

    JAC-Antimicrobial Resistance, Vol. 2, Núm. 4

2019

  1. Activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and Enterobacterales isolates recovered from intensive care unit patients in Spain: The SUPERIOR multicentre study

    International Journal of Antimicrobial Agents, Vol. 53, Núm. 5, pp. 682-688

  2. Monitoring the antimicrobial susceptibility of gram-negative organisms involved in intraabdominal and urinary tract infections recovered during the smart study (Spain, 2016 and 2017)

    Revista Espanola de Quimioterapia, Vol. 32, Núm. 2, pp. 145-155

2018

  1. Antimicrobial susceptibility trends and evolution of isolates with extended spectrum β-lactamases among gram-negative organisms recovered during the SMART study in Spain (2011-2015)

    Revista Espanola de Quimioterapia, Vol. 31, Núm. 2, pp. 136-145

  2. Management of multidrug resistant Gram-negative bacilli infections in solid organ transplant recipients: SET/GESITRA-SEIMC/REIPI recommendations

    Transplantation Reviews, Vol. 32, Núm. 1, pp. 36-57